

# Susan L Cohn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/358758/publications.pdf>

Version: 2024-02-01

192  
papers

17,538  
citations

19657

61  
h-index

15266

126  
g-index

194  
all docs

194  
docs citations

194  
times ranked

12045  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroblastoma. <i>Lancet</i> , The, 2007, 369, 2106-2120.	13.7	1,856
2	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 289-297.	1.6	1,540
3	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. <i>New England Journal of Medicine</i> , 2010, 363, 1324-1334.	27.0	1,460
4	The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 298-303.	1.6	869
5	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3008-3017.	1.6	637
6	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. <i>New England Journal of Medicine</i> , 2005, 353, 2243-2253.	27.0	495
7	Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project. <i>Radiology</i> , 2011, 261, 243-257.	7.3	386
8	Expression of the Gene for Multidrug-Resistance-associated Protein and Outcome in Patients with Neuroblastoma. <i>New England Journal of Medicine</i> , 1996, 334, 231-238.	27.0	295
9	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 985-993.	1.5	285
10	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. <i>New England Journal of Medicine</i> , 2010, 363, 1313-1323.	27.0	253
11	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2011, 29, 3286-3292.	1.6	248
12	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 999-1008.	10.7	246
13	Advances in the Diagnosis and Treatment of Neuroblastoma. <i>Oncologist</i> , 2003, 8, 278-292.	3.7	233
14	Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4969-4975.	1.6	220
15	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2017, 35, 2580-2587.	1.6	219
16	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. <i>Journal of Clinical Oncology</i> , 2012, 30, 1842-1848.	1.6	174
17	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
18	Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. <i>Journal of Nuclear Medicine</i> , 2013, 54, 541-548.	5.0	169

#	ARTICLE	IF	CITATIONS
19	Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1546-1553.	1.6	155
20	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 3169-3176.	1.6	154
21	A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants. <i>Annals of Surgery</i> , 2012, 256, 573-580.	4.2	152
22	Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group. , 1997, 28, 284-288.		151
23	TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma. <i>Cell Reports</i> , 2014, 7, 1343-1352.	6.4	146
24	Hyperdiploidy Plus Nonamplified <i>MYCN</i> Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6466-6473.	1.6	135
25	SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. <i>Cancer Research</i> , 2002, 62, 7357-63.	0.9	134
26	Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2284-2292.	1.6	128
27	Modulation of matrix remodeling by SPARC in neoplastic progression. <i>Seminars in Cell and Developmental Biology</i> , 2010, 21, 55-65.	5.0	128
28	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	3.0	128
29	Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 547-553.	4.1	127
30	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 208-213.	1.6	127
31	Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4351-4357.	1.6	124
32	Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. <i>Journal of Pediatrics</i> , 1994, 125, 712-716.	1.8	117
33	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1236-1251.	6.3	113
34	Significance of <i>MYCN</i> Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2009, 27, 365-370.	1.6	111
35	Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 76-82.	1.6	109
36	MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN. <i>Journal of Clinical Oncology</i> , 2000, 18, 3604-3613.	1.6	100

#	ARTICLE	IF	CITATIONS
37	Treatment and Outcome of 83 Children With Intraspinal Neuroblastoma: The Pediatric Oncology Group Experience. <i>Journal of Clinical Oncology</i> , 2001, 19, 1047-1055.	1.6	100
38	SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. <i>International Journal of Cancer</i> , 2006, 118, 310-316.	5.1	100
39	Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3808-3815.	1.6	100
40	A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1994, 331, 1680-1684.	27.0	99
41	Methylation of <i>CASP8</i> , <i>DCR2</i> , and <i>HIN-1</i> in Neuroblastoma Is Associated with Poor Outcome. <i>Clinical Cancer Research</i> , 2007, 13, 3191-3197.	7.0	98
42	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. <i>Clinical Cancer Research</i> , 2021, 27, 2179-2189.	7.0	95
43	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , 2011, 47, 561-571.	2.8	94
44	Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3909-3915.	1.6	89
45	Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2011, 17, 6858-6866.	7.0	88
46	Natural History and Biology of Stage A Neuroblastoma: A Pediatric Oncology Group Study. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 197-205.	1.3	87
47	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. <i>Cancer Research</i> , 2003, 63, 6299-310.	0.9	85
48	Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 1716-1724.	0.9	84
49	Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2004, 10, 8493-8500.	7.0	81
50	Detection of MYCN Gene Amplification in Neuroblastoma by Fluorescence In Situ Hybridization: A Pediatric Oncology Group Study. <i>Neoplasia</i> , 2001, 3, 105-109.	5.3	79
51	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. <i>Pediatric Blood and Cancer</i> , 2009, 53, 563-569.	1.5	79
52	The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma. <i>Cancer Research</i> , 2006, 66, 2826-2833.	0.9	78
53	Residential Pesticide Exposure and Neuroblastoma. <i>Epidemiology</i> , 2001, 12, 20-27.	2.7	77
54	MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. <i>Oncogene</i> , 2004, 23, 753-762.	5.9	76

#	ARTICLE	IF	CITATIONS
55	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8819-8827.	1.6	74
56	Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2014, 61, 627-635.	1.5	71
57	Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age. <i>Journal of Clinical Oncology</i> , 2011, 29, 4358-4364.	1.6	69
58	Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 913-918.	1.6	67
59	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. <i>Cancer</i> , 2013, 119, 3718-3726.	4.1	67
60	Long-term outcome of patients with intraspinal neuroblastoma. <i>Medical and Pediatric Oncology</i> , 1999, 32, 353-359.	1.0	66
61	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1349-1356.	1.5	66
62	Preferential amplification of the paternal allele of the myc gene in human neuroblastomas. <i>Nature Genetics</i> , 1993, 4, 191-194.	21.4	65
63	Treatment of Relapsed Wilms' Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children's Memorial Hospital. <i>Journal of Clinical Oncology</i> , 2004, 22, 2885-2890.	1.6	64
64	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 2715-2721.	7.0	62
65	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 3243-3255.	1.6	61
66	Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , 2017, 72, 177-185.	2.8	59
67	MYCN amplification remains prognostically strong 20 years after its clinical debut. <i>European Journal of Cancer</i> , 2004, 40, 2639-2642.	2.8	58
68	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2008, 51, 589-592.	1.5	58
69	Coamplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 196-203.	2.8	56
70	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. <i>European Journal of Cancer</i> , 2016, 65, 1-10.	2.8	56
71	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 6142-6149.	7.0	55
72	Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. <i>Genomics</i> , 1991, 10, 293-297.	2.9	54

#	ARTICLE	IF	CITATIONS
73	Clinical Impact and Prognostic Value of Metaiodobenzylguanidine Imaging in Children With Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1999, 21, 13-18.	0.6	54
74	HuD, a Neuronal-specific RNA-binding Protein, Increases their <i>Vivo</i> Stability of MYCN RNA. <i>Journal of Biological Chemistry</i> , 2002, 277, 1967-1973.	3.4	53
75	Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. <i>Cancer Letters</i> , 2005, 228, 283-299.	7.2	53
76	Secreted Protein Acidic and Rich in Cysteine Is a Matrix Scavenger Chaperone. <i>PLoS ONE</i> , 2011, 6, e23880.	2.5	52
77	Second malignancies in patients with neuroblastoma: The effects of risk-based therapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 128-133.	1.5	51
78	The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. <i>Cancer Letters</i> , 2005, 228, 257-266.	7.2	48
79	Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. <i>Cancer</i> , 1988, 62, 723-726.	4.1	47
80	Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC. <i>Cancer Research</i> , 2004, 64, 7420-7425.	0.9	47
81	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4882-4887.	7.0	45
82	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1111-1115.	7.0	45
83	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2018, 24, 189-196.	7.0	45
84	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 115-124.	1.6	45
85	Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. <i>Modern Pathology</i> , 2009, 22, 950-958.	5.5	44
86	Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. <i>Molecular Cancer</i> , 2010, 9, 138.	19.2	44
87	Genetic discoveries and treatment advances in neuroblastoma. <i>Current Opinion in Pediatrics</i> , 2016, 28, 19-25.	2.0	44
88	The spectrum of metabolic bone disease in lymphoblastic leukemia. <i>Cancer</i> , 1987, 59, 346-350.	4.1	43
89	Cross-Talk between Schwann Cells and Neuroblasts Influences the Biology of Neuroblastoma Xenografts. <i>American Journal of Pathology</i> , 2005, 166, 891-900.	3.8	43
90	The challenge of defining "ultra-high-risk" neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27556.	1.5	43

#	ARTICLE	IF	CITATIONS
91	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. <i>Journal of Clinical Oncology</i> , 2020, 38, 1906-1918.	1.6	41
92	Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1350-1356.	1.5	40
93	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 25-34.	5.6	38
94	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
95	Modulation of N-myc expression alters the invasiveness of neuroblastoma. <i>Clinical and Experimental Metastasis</i> , 1997, 15, 130-139.	3.3	36
96	The regulation of angiogenesis in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 47-52.	7.2	36
97	Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 895-905.	2.1	36
98	Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human Neuroblastoma. <i>Cancer Research</i> , 2004, 64, 4531-4538.	0.9	35
99	Does <i>MYCN</i> Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2006, 12, 5693-5697.	7.0	35
100	Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma. <i>Clinical Cancer Research</i> , 2007, 13, 3499-3506.	7.0	35
101	Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. <i>Cancer Research</i> , 2012, 72, 4714-4723.	0.9	35
102	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. <i>Pediatric and Developmental Pathology</i> , 2014, 17, 441-449.	1.0	35
103	Differential Activity of ELAV-like RNA-binding Proteins in Human Neuroblastoma. <i>Journal of Biological Chemistry</i> , 1996, 271, 33587-33591.	3.4	34
104	Binding of a 40-kDa Protein to the N-myc 3' Untranslated Region Correlates with Enhanced N-myc Expression in Human Neuroblastoma. <i>Journal of Biological Chemistry</i> , 1996, 271, 33580-33586.	3.4	34
105	High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. <i>Cancer Genetics and Cytogenetics</i> , 2007, 174, 100-110.	1.0	34
106	Unrealistic parental expectations for cure in poor-prognosis childhood cancer. <i>Cancer</i> , 2020, 126, 416-424.	4.1	34
107	Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. <i>Oncotarget</i> , 2016, 7, 76816-76826.	1.8	33
108	Natural killer cell lymphoma. <i>Cancer</i> , 2001, 91, 642-646.	4.1	32

#	ARTICLE	IF	CITATIONS
109	Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1932-1939.	1.5	32
110	Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter <sup>®</sup> system. <i>Molecular Oncology</i> , 2014, 8, 669-678.	4.6	32
111	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. <i>Oncotarget</i> , 2018, 9, 6416-6432.	1.8	31
112	Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. <i>Journal of the National Cancer Institute</i> , 2012, 105, 302-309.	6.3	30
113	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28794.	1.5	29
114	Advances in the diagnosis and treatment of neuroblastoma. <i>Current Opinion in Oncology</i> , 1998, 10, 43-51.	2.4	28
115	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. <i>Targeted Oncology</i> , 2012, 7, 199-210.	3.6	28
116	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 1228-1235.	1.6	28
117	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28359.	1.5	28
118	Positive association between congenital anomalies and risk of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2005, 45, 649-655.	1.5	27
119	Emerging and investigational therapies for neuroblastoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 355-368.	0.8	27
120	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 782-789.	1.2	27
121	Cross-talk between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis. <i>Cancer Letters</i> , 2005, 228, 125-131.	7.2	26
122	New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. <i>Pediatric Blood and Cancer</i> , 2012, 58, 1099-1105.	1.5	26
123	Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 656-658.	1.0	25
124	Using Germline Genomics to Individualize Pediatric Cancer Treatments. <i>Clinical Cancer Research</i> , 2012, 18, 2791-2800.	7.0	25
125	Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. <i>Pediatric Blood and Cancer</i> , 2013, 60, 363-370.	1.5	25
126	Data Commons to Support Pediatric Cancer Research. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 746-752.	3.8	25



#	ARTICLE	IF	CITATIONS
127	Comparative pharmacokinetics, safety, and tolerability of two sources of ch14,18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 405-412.	2.3	24
128	The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. <i>Pediatric Blood and Cancer</i> , 2011, 56, 164-167.	1.5	23
129	Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. <i>Pediatric Blood and Cancer</i> , 2012, 59, 642-647.	1.5	23
130	Efavirenz-but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant. <i>Journal of the International AIDS Society</i> , 2014, 17, 19484.	3.0	23
131	Present Status of Serum Tumor Markers in Diagnosis, Prognosis, and Evaluation of Therapy. <i>Cancer Investigation</i> , 1986, 4, 305-327.	1.3	22
132	Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. <i>BMC Cancer</i> , 2010, 10, 286.	2.6	22
133	Clinical outcome in children with recurrent neuroblastoma treated with ABT751 and effect of ABT751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. <i>Pediatric Blood and Cancer</i> , 2010, 54, 47-54.	1.5	22
134	Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 507-516.	4.1	22
135	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1309-1317.	7.0	22
136	Protocol for the Examination of Specimens From Patients With Neuroblastoma and Related Neuroblastic Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 874-883.	2.5	22
137	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
138	Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	20
139	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-15.	2.1	20
140	Data Commons to Support Pediatric Cancer Research. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 746-752.	3.8	20
141	Identification of different <i>ALK</i> mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. <i>Oncotarget</i> , 2016, 7, 87301-87311.	1.8	20
142	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. <i>Pediatric Blood and Cancer</i> , 2006, 46, 719-722.	1.5	19
143	Evidence for Molecular Heterogeneity in Human Ganglioneuroblastoma. <i>Pediatric Pathology</i> , 1993, 13, 787-796.	0.5	18
144	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1034-1043.	2.1	18

#	ARTICLE	IF	CITATIONS
145	Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2008, 50, 679-680.	1.5	17
146	Management of Tumor Lysis Syndrome: Need for Evidence-Based Guidelines. <i>Journal of Clinical Oncology</i> , 2008, 26, 5657-5658.	1.6	17
147	Progress in Defining and Treating High-Risk Neuroblastoma: Lessons From the Bench and Bedside. <i>Journal of Clinical Oncology</i> , 2009, 27, 1003-1004.	1.6	17
148	Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 472-474.	1.5	17
149	Antiangiogenic therapy inhibits human neuroblastoma growth. <i>Medical and Pediatric Oncology</i> , 2001, 36, 190-193.	1.0	16
150	Excellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2006, 41, 271-276.	1.6	16
151	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 737-743.	2.3	16
152	Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBLO621). <i>Pediatric Blood and Cancer</i> , 2014, 61, 990-996.	1.5	16
153	Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. <i>Biology of Blood and Marrow Transplantation</i> , 1998, 4, 38-42.	2.0	15
154	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. <i>European Journal of Cancer</i> , 2012, 48, 1185-1191.	2.8	14
155	5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	14
156	Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. <i>Oncotarget</i> , 2016, 7, 77696-77706.	1.8	14
157	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1019-1023.	1.5	13
158	3 + 3 (Rolling) 6. <i>Journal of Clinical Oncology</i> , 2008, 26, 170-171.	1.6	11
159	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 4107-4118.	1.6	11
160	Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 452-459.	2.0	10
161	Stage 4S Neuroblastoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1075-1081.	3.7	10
162	Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 553-557.	2.8	9

#	ARTICLE	IF	CITATIONS
163	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27736.	1.5	8
164	Gastrointestinal relapse of leukemia, mimicking acute graft vs. host disease, following a stem cell transplant. , 2000, 34, 287-289.		7
165	Synergy between 5' and 3' flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells. <i>Neuroscience Letters</i> , 2000, 292, 147-150.	2.1	7
166	Genetically Informed Therapies for Children with Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2735-2739.	7.0	7
167	Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo. <i>Medical and Pediatric Oncology</i> , 2000, 35, 590-592.	1.0	6
168	Are molecular neuroblastoma classifiers ready for prime time?. <i>Lancet Oncology</i> , The, 2009, 10, 641-642.	10.7	6
169	Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2232-2234.	1.5	6
170	Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28390.	1.5	6
171	Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretinoin alone or observation. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1104-1106.	1.5	5
172	Surveillance of Childhood Cancer Survivors: A Lifelong Affair. <i>Journal of Clinical Oncology</i> , 2015, 33, 3531-3532.	1.6	5
173	Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26226.	1.5	5
174	Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. <i>JAMA Network Open</i> , 2021, 4, e2116248.	5.9	5
175	Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. <i>Cancer</i> , 2022, 128, 2967-2977.	4.1	5
176	Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27417.	1.5	4
177	Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours. <i>Medical and Pediatric Oncology</i> , 2001, 36, 48-51.	1.0	3
178	Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. <i>Pediatric Blood and Cancer</i> , 2013, 60, 332-335.	1.5	3
179	The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for <sup>131</sup> I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. , 2022, 39, 304-316.		3
180	Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1181-1188.	2.1	3

#	ARTICLE	IF	CITATIONS
181	Treatment of Neuroblastoma. <i>Pediatric Oncology</i> , 2005, , 123-192.	0.5	2
182	A Selfless Act. <i>Journal of Clinical Oncology</i> , 2015, 33, 3834-3835.	1.6	2
183	The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. <i>Journal of Pediatric Oncology Nursing</i> , 2017, 34, 160-172.	1.5	2
184	Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28218.	1.5	1
185	Neuroblastoma: solving a biologic puzzle. <i>Cancer Treatment and Research</i> , 1997, 92, 125-162.	0.5	1
186	Rethinking high-risk neuroblastoma treatment. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29730.	1.5	1
187	Locoregional MYCN-amplified neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 736-738.	1.5	0
188	Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. <i>Pediatric Blood and Cancer</i> , 2013, 60, 512-514.	1.5	0
189	Reply to K. Beiske et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3720-3721.	1.6	0
190	Secreted Protein Acidic and Rich in Cysteine. , 2014, , 1-6.		0
191	Secreted Protein Acidic and Rich in Cysteine. , 2014, , 4147-4151.		0
192	Advances in the treatment of neuroblastoma. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 865-7.	0.3	0